The influence of different sample collection types on the levels of markers used for Down's syndrome screening as measured by the Kryptor Immunosassay system

被引:22
作者
Spencer, K [1 ]
机构
[1] Harold Wood Hosp, Dept Clin Biochem, Romford RM3 0BE, Essex, England
关键词
D O I
10.1258/000456303763046102
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background In a rapid point-of-care screening programme for chromosomal anomalies, analysis of biochemical markers in maternal blood can now be accomplished in a rapid time frame (less than 20 min). The need to leave whole blood samples some 10 min for coagulation and a further 5 min for centrifugation adds additional processing time. Methods The possibilities for reducing this processing time were investigated using various anticoagulated blood collection systems and the Kryptor analytical platform. Plasma levels of alpha-fetoprotein (AFP), pregnancy-associated plasma protein-A (PAPP-A) and free human chronic gonadotrophin beta-subunit (beta-hCG) were compared with those in maternal serum. Results From the mean results from ten patients it was shown that use of heparin plasma resulted in a statistically significant reduction in levels of PAPP-A and that EDTA plasma reduced the levels of PAPP-A dramatically. For AFP, levels in citrated plasma and EDTA plasma were also significantly reduced, whereas levels of free beta-hCG were not affected. Conclusion Use of alternative sample types for PAPP-A is not possible. The sample of choice for first trimester screening using the Kryptor platform is maternal serum.
引用
收藏
页码:166 / 168
页数:3
相关论文
共 10 条
[1]   INTERACTION BETWEEN HEPARIN AND HUMAN PREGNANCY-ASSOCIATED PLASMA PROTEIN-A (PAPP-A) - A SIMPLE PURIFICATION PROCEDURE [J].
DAVEY, MW ;
TEISNER, B ;
SINOSICH, M ;
GRUDZINSKAS, JG .
ANALYTICAL BIOCHEMISTRY, 1983, 131 (01) :18-24
[2]  
OXVIG C, 1993, J BIOL CHEM, V268, P12243
[3]  
Qin QP, 2002, CLIN CHEM, V48, P473
[4]  
SINOSICH MJ, 1981, AUST NZ J MED, V4, P429
[5]   One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester [J].
Spencer, K ;
Spencer, CE ;
Power, M ;
Moakes, A ;
Nicolaides, KH .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2000, 107 (10) :1271-1275
[6]  
Spencer K, 2002, CLIN CHEM, V48, P403
[7]   A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A [J].
Spencer, K ;
Souter, V ;
Tul, N ;
Snijders, R ;
Nicolaides, KH .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 1999, 13 (04) :231-237
[8]  
SPENCER K, IN PRESS BR J OBSTET
[9]   EFFECT OF ANTI-COAGULANT ON THE MEASUREMENT OF PREGNANCY-ASSOCIATED PLASMA PROTEIN-A (PAPP-A) [J].
TOOP, KM ;
KLOPPER, A .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1983, 90 (02) :150-155
[10]   SPECIFIC AND REVERSIBLE INTERACTION BETWEEN PREGNANCY-ASSOCIATED PLASMA PROTEIN-A AND HEPARIN [J].
WESTERGAARD, JG ;
HAU, J ;
TEISNER, B ;
GRUDZINSKAS, JG .
PLACENTA, 1983, 4 (01) :13-18